{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Lymphomas+%28Phase+1%29&page=12",
    "query": {
      "condition": "B-cell Lymphomas (Phase 1)",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 1137,
    "total_pages": 114,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Lymphomas+%28Phase+1%29&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Lymphomas+%28Phase+1%29&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T12:32:36.088Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01786135",
      "title": "A Safety Study of SGN-CD19A for B-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Burkitt Lymphoma",
        "Lymphoma, Follicular",
        "Lymphoma, Large B-Cell, Diffuse",
        "Lymphoma, Mantle-Cell",
        "Precursor B-cell Lymphoblastic Leukemia-Lymphoma"
      ],
      "interventions": [
        {
          "name": "SGN-CD19A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2013-02",
      "completion_date": "2017-02-16",
      "has_results": false,
      "last_update_posted_date": "2017-10-19",
      "last_synced_at": "2026-10-12T12:32:36.088Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Duarte, California • Stanford, California + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01786135"
    },
    {
      "nct_id": "NCT00005967",
      "title": "Tipifarnib in Treating Patients With Advanced Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "tipifarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2000-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-10-12T12:32:36.088Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005967"
    },
    {
      "nct_id": "NCT07572136",
      "title": "Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-All",
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "TSLPR-CART",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 57,
      "start_date": "2026-10-14",
      "completion_date": "2032-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-12T12:32:36.088Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07572136"
    },
    {
      "nct_id": "NCT00002663",
      "title": "Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "EBV-induced Lymphomas",
        "EBV-associated Malignancies",
        "Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma"
      ],
      "interventions": [
        {
          "name": "Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Atara Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 58,
      "start_date": "1995-03",
      "completion_date": "2019-07",
      "has_results": true,
      "last_update_posted_date": "2023-02-13",
      "last_synced_at": "2026-10-12T12:32:36.088Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002663"
    },
    {
      "nct_id": "NCT01088763",
      "title": "Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Atypical Teratoid/Rhabdoid Tumor",
        "Childhood Central Nervous System Choriocarcinoma",
        "Childhood Central Nervous System Germinoma",
        "Childhood Central Nervous System Mixed Germ Cell Tumor",
        "Childhood Central Nervous System Teratoma",
        "Childhood Central Nervous System Yolk Sac Tumor",
        "Childhood Choroid Plexus Tumor",
        "Childhood Craniopharyngioma",
        "Childhood Ependymoblastoma",
        "Childhood Grade I Meningioma",
        "Childhood Grade II Meningioma",
        "Childhood Grade III Meningioma",
        "Childhood Infratentorial Ependymoma",
        "Childhood Medulloepithelioma",
        "Childhood Mixed Glioma",
        "Childhood Oligodendroglioma",
        "Childhood Supratentorial Ependymoma",
        "Gonadotroph Adenoma",
        "Pituitary Basophilic Adenoma",
        "Pituitary Chromophobe Adenoma",
        "Pituitary Eosinophilic Adenoma",
        "Prolactin Secreting Adenoma",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Anaplastic Large Cell Lymphoma",
        "Recurrent Childhood Brain Stem Glioma",
        "Recurrent Childhood Central Nervous System Embryonal Tumor",
        "Recurrent Childhood Cerebellar Astrocytoma",
        "Recurrent Childhood Cerebral Astrocytoma",
        "Recurrent Childhood Ependymoma",
        "Recurrent Childhood Grade III Lymphomatoid Granulomatosis",
        "Recurrent Childhood Large Cell Lymphoma",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "Recurrent Childhood Medulloblastoma",
        "Recurrent Childhood Pineoblastoma",
        "Recurrent Childhood Small Noncleaved Cell Lymphoma",
        "Recurrent Childhood Spinal Cord Neoplasm",
        "Recurrent Childhood Subependymal Giant Cell Astrocytoma",
        "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor",
        "Recurrent Childhood Visual Pathway and Hypothalamic Glioma",
        "Recurrent Childhood Visual Pathway Glioma",
        "Recurrent Pituitary Tumor",
        "Recurrent/Refractory Childhood Hodgkin Lymphoma",
        "T-cell Childhood Acute Lymphoblastic Leukemia",
        "T-cell Large Granular Lymphocyte Leukemia",
        "TSH Secreting Adenoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "gamma-secretase/Notch signalling pathway inhibitor RO4929097",
          "type": "DRUG"
        },
        {
          "name": "diagnostic laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 129,
      "start_date": "2010-03",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2014-11-05",
      "last_synced_at": "2026-10-12T12:32:36.088Z",
      "location_count": 11,
      "location_summary": "Palo Alto, California • Stanford, California • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01088763"
    },
    {
      "nct_id": "NCT00004230",
      "title": "Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "captopril",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "autologous bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 35,
      "start_date": "1999-10",
      "completion_date": "2002-03",
      "has_results": false,
      "last_update_posted_date": "2012-06-06",
      "last_synced_at": "2026-10-12T12:32:36.088Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004230"
    },
    {
      "nct_id": "NCT03287817",
      "title": "Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)"
      ],
      "interventions": [
        {
          "name": "AUTO3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Autolus Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2017-09-05",
      "completion_date": "2023-10-19",
      "has_results": true,
      "last_update_posted_date": "2025-07-14",
      "last_synced_at": "2026-10-12T12:32:36.088Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Denver, Colorado • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03287817"
    },
    {
      "nct_id": "NCT01943682",
      "title": "Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Burkitt Lymphoma",
        "Diffuse Large Cell Lymphoma",
        "Gray Zone Lymphoma",
        "Lymphoblastic Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "CPX-351",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "12 Months to 30 Years"
      },
      "enrollment_count": 27,
      "start_date": "2013-09",
      "completion_date": "2019-04",
      "has_results": false,
      "last_update_posted_date": "2020-11-09",
      "last_synced_at": "2026-10-12T12:32:36.088Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01943682"
    },
    {
      "nct_id": "NCT00024180",
      "title": "FR901228 in Treating Patients With Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "romidepsin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2002-01",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2013-01-31",
      "last_synced_at": "2026-10-12T12:32:36.088Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00024180"
    },
    {
      "nct_id": "NCT00103779",
      "title": "A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "SGN-40 (anti-huCD40 mAb)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2004-12",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2014-12-18",
      "last_synced_at": "2026-10-12T12:32:36.088Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Stanford, California • Miami, Florida + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00103779"
    }
  ]
}